5d 1m 3m 1y 5y 10y
There is research on this stock available only to PRO subscribers.
Marketwire (Feb 27, 2014)
Marketwire (Jan 27, 2014)
Marketwire (Dec 10, 2013)
BIO vs. ETF Alternatives
Bio-Rad Laboratories Inc., manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials.
Tuesday, May 72013, 4:46 PM
Wednesday, Feb 272013, 1:35 PMShares of Bio-Rad (BIO +5%) move higher today after a solid Q4 earnings beat. Total sales rose 4.3% Y/Y, which was offset somewhat by a decline in gross margin to 55.9% from 56.5%. Sidoti upgrades the stock to Buy on the back of the upbeat report, while Jefferies ups its price target to $140 from $124 on higher cash flow forecasts. |Wednesday, Feb 272013, 1:35 PM| Comment!
Tuesday, May 12012, 5:03 PM
Tuesday, Apr 32012, 12:22 PMBio-Rad Labs (BIO +12.3%) shares surge after the company says it has extended its marketing deal with research tool maker Luminex (LMNX +0.2%). Under the deal, BIO will hold the worldwide sales and distribution rights to LMNX's Magpix multiplexing instrument. |Tuesday, Apr 32012, 12:22 PM| Comment!
Tuesday, Jul 52011, 10:16 AMTPG's acquisition of Immucor (BLUD +30%) fails to spur comparables Bio-Rad Laboratories (BIO -0.7%) and Gen-Probe (GPRO -1.1%). Takeout multiples were below current diagnostics multiples, Leerink notes, and the P-E buyout likely means there was little interest in BLUD from strategic acquirers. |Tuesday, Jul 52011, 10:16 AM| 1 Comment